UBT251 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Investigational long-acting synthetic peptide GLP-1/GIP/glucagon triple receptor agonist compound Reference needs_revision Best effort · source review pending

Also known as: UBT251 injection, NN9559

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

UBT251 is an investigational triple agonist peptide targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Public clinical development has evaluated once-weekly subcutaneous administration in obesity, overweight, type 2 diabetes, and related metabolic conditions.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Administration Routes (Research)

subcutaneous injection

Reported Research Effects

Activates GLP-1, GIP, and glucagon receptors as a peptide triple agonist
In a phase 1a/1b clinical study, once-weekly treatment was associated with reductions in body weight, fasting plasma glucose, glycated hemoglobin, and lipid parameters; these are study findings and not established therapeutic claims
Decreased appetite and gastrointestinal adverse events were among the commonly reported adverse effects in the phase 1a/1b study

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Clinical and pharmacology information is limited to investigational studies and authoritative development disclosures. No reliably supported chemical structure, molecular formula, molecular weight, solubility, storage specification, or terminal half-life was identified in the authoritative sources reviewed. Common reference package sizes are not an appropriate established scientific/catalog fact for this investigational compound, so commonSizes is left empty.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

PMID 42712041; DOI 10.1111/dom.71327; ClinicalTrials.gov NCT07134335; ClinicalTrials.gov NCT07668388; Novo Nordisk development code NN9559

Source-Backed Observations

UBT251 is in clinical development and is not established here as an approved medicine. A 2026 phase 1a/1b publication described single ascending subcutaneous doses from 0.1 to 4.5 mg and once-weekly subcutaneous administration for 12 weeks at 1, 3, and 6 mg in participants with overweight or obesity. A registered phase 2 CKD study describes once-weekly subcutaneous dose-escalation regimens targeting maintenance doses of 2, 4, or 6 mg.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study
https://pubmed.ncbi.nlm.nih.gov/42712041/ (accessed 2026-09-20)

Study Details: NCT07134335, UBT251 Injection Phase II Clinical Study (CKD)
https://clinicaltrials.gov/study/NCT07134335 (accessed 2026-09-20)

Study Details: NCT07668388, A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
https://clinicaltrials.gov/study/NCT07668388 (accessed 2026-09-20)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.